Planned launch of OptiBiotix products with Boots
RNS & Investor News
31 August 2021
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that Stephen O'Hara, CEO of OptiBiotix will
provide a live presentation to investors via the Investor Meet Company platform on Thursday, 9 September 2021 at 2pm BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation. Investors can sign
up to Investor Meet Company for free and add to meet OptiBiotix.
To register for the presentation, please use this link: https://www.investormeetcompany.com/optibiotix-health-plc/register-investor
Investors who already follow OptiBiotix on the Investor Meet Company platform will automatically be invited.
For further information, please contact:
|OptiBiotix Health plc||www.optibiotix.com|
|Neil Davidson, Chairman||Contact via Walbrook below|
|Stephen O'Hara, Chief Executive|
|Cenkos Securities plc (Broker)||Tel: 020 7397 8900|
|Callum Davidson / Neil McDonald|
|Michael Johnson / Russell Kerr (Sales)|
|Walbrook PR Ltd||Mob: 07876 741 001|
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and
OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare
supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.
ProBiotix Health anticipating "big commercial opportunities" during 2023
Group CEO Stephen O’Hara and CEO Steen Anderson | 04 January 2023